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Abstract
Background: The lower third of the nose is one of the most important cosmetic units of the face, and its
reconstructive techniques remain a big challenge. As an alternative approach to repair or regenerate the nasal
tissue, the biomaterial-based strategy has been extensively investigated. The aim of this study is to determine the
safety and efficacy of human acellular amniotic membrane (HAAM) to repair the full-thickness defects in the lower
third of the nose in humans.
Methods: In this study, 180 patients who underwent excision of skin lesions of the lower third of the nose from
2012 to 2016 were included; of the patients, 92 received HAAM and Vaseline gauze treatments, and the other 88
patients received Vaseline gauze treatment only. The haemostasis time and the duration of operation were
recorded during surgery; after surgery, the time to pain disappearance, scab formation and wound healing, and the
wound healing rate were measured.
Results: Immediately after the HAAM implantation, a reduction of the haemostasis time and an accelerated
disappearance of pain were observed. Compared with the control group, the formation and detachment of scab in
patients who received the HAAM implantation were notably accelerated, postoperatively. When the diameter of the
lesion exceeded 5mm, the HAAM implantation was found to enhance the wound healing, although this
enhancement was not seen when the diameter was less than 5 mm. Additionally, the HAAM implantation
significantly reduced bleeding, wound infection and scar formation, postoperatively.
Conclusions: HAAM-assisted healing is a promising therapy for lower third nasal reconstruction leading to rapid
wound healing and fewer complications and thus has considerable potential for extensive clinical application in
repairing skin wounds.
Trial registration: ChiCTR1800017618, retrospectively registered on July 08, 2018.
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Background
The lower third of the nose is composed of the bilateral ala
and soft triangles, the central tip and columella; its topog-
raphy is characterised by interwoven concavities, convex-
ities and varying skin thickness [1]. As one of the most
important cosmetic units of the face, the lower third nasal
reconstruction remains a big challenge for reconstructive
surgeons and researchers. The ideal reconstruction should
restore the normal anatomy while limiting the flaws to the
nasal cosmetic unit. To achieve this goal, a myriad of
reconstructive strategies have been developed that include
numerous flaps and skin grafting [1–3].However, interest in
developing alternative approaches of reconstruction—par-
ticularly biomaterial-based methods that repair or regener-
ate the nasal tissue—is growing [4, 5].
Human amniotic membrane (AM) has been long used
as an attractive biomaterial for skin defect healing.
Taken from the innermost layer of the placenta, the
human AM is highly abundant and readily available
without invasive harvesting and ethical concerns. Several
decades ago, the fresh and fresh-frozen human AM were
used to dress partial-thickness burns in humans, offering
substantial pain relief [6, 7]. Human AM also prevents
infection and accelerates healing in the treatment of
chronic ulcers [8, 9], necrotising fasciitis [10], epidermo-
lysis bullosa [11] and other cutaneous diseases [12].
Similar outcomes were determined after the human AM
was dehydrated or freeze-dried [13–16].
Decellularised AM was developed to prevent sensitisa-
tion and immune reactions, minimise potential infection
and reduce the high costs related to the application of liv-
ing cellularised graft [17]. While human acellular AM
(HAAM) provides a nearly unlimited source for skin
defect healing, it is unknown whether HAAM possesses
the potential to repair nasal tissue in humans. After the
procedure of decellularisation and dehydration was
defined [18], the three-dimensional HAAM was found to
be capable of supporting the attachment and proliferation
of allogenic cells [19], it was further determined that
HAAM increased the epidermal thickness and improved
epidermal healing in mice [20, 21], rats [22] and pigs [23].
These achievements accelerated the clinical application of
HAAM for nasal skin defects reconstruction.
While the lower third of the nose is critical for the
aesthetic appearance of the face, this region is commonly
affected by unintended and deliberate injuries. This clin-
ical study therefore investigates the safety and feasibility
of implanting HAAM to repair successfully the
full-thickness defects in the lower third of the nose.
Methods
Preparation of HAAM
The HAAM was provided by Chengdu Qingshan Likang
Pharmaceutical Co., Ltd., which has been approved by
the China Food and Drug Administration. The manufac-
ture process (Chinese patent no. ZL200410036792.4)
was conducted according to the Good Manufacturing
Practice in People’s Republic of China. In brief,
the HAAM was separated from the placentas of con-
senting mothers and rinsed with sterile distilled water to
remove the residual blood. Serological examination was
performed to exclude the possibility of human immuno-
deficiency virus type I, syphilis and human hepatitis
virus types B and C. The fresh HAAM was submerged
in a solution of methanol and chloroform, rinsed with
sterile distilled water and perfused with sodium dodecyl
sulfate (SDS, Sigma) in distilled water for at least 5 h.
The decellularisation process was done using 0.25% tryp-
sin for 6 h and was then rinsed with a saline solution.
The HAAM was freeze-dried under a vacuum, cut into
pieces 1 cm × 1 cm, packed into hermetic packages and
sterilised with gamma radiation. The HAAM was stored
aseptically at room temperature until implantation.
Histology and scanning electron microscope (SEM) analysis
The HAAM cut into sizes of 0.5 × 0.5 cm was stained dir-
ectly with hematoxylin and eosin (H&E); also, it was
embedded in paraffin wax and cut into 5-μm-thick sec-
tions for H&E staining for cross-section observation. In
addition, the HAAM was subjected to critical point drying
and the ultrastructure was observed using a SEM.
Patients
From July 2012 to August 2016, 180 patients from West
China Hospital (Chengdu, Sichuan, People’s Republic of
China) who underwent excisions of skin lesions of the
lower third of the nose and secondary healing were in-
cluded in this study. The inclusion criteria were (1) patients
who had directly excisable lesions at the nasal tip or ala nasi
regions and underwent secondary healing, (2) no abnormal-
ity during preoperative examination and (3) no infection at
the surgical areas. The exclusion criteria were (1) patients
aged younger than 12 years, (2) patients whose defects were
unsuitable for secondary healing and (3) patients who had a
long-term history of chronic diseases, such as diabetes,
renal failure, or immunosuppression. All patients were in-
formed of the full content of the clinical trial and signed
the consent forms preoperatively. This trial has been regis-
tered in Chinese Clinical Trial Registry with the registration
number ChiCTR1800017618. This study was approved by
Ethical Committee of West China Hospital, Sichuan
University.
Groups and surgical procedures
The surgeries were performed by the same team at the De-
partment of Dermatology and Venereology, West China
Hospital, Sichuan University. The included patients were
randomly assigned to either the HAAM treatment group
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or the control group (Vaseline gauze treatment) by the
randomisation serial numbers from the statistical program
SPSS software (SPSS 19.0; IBM., Armonk, NY, USA). The
following details of all patients were recorded: gender, age,
location of skin lesions, size of skin defects after skin lesion
excision, postoperative complications (bleeding, infection,
hematoma and appearance impairment) and recurrence
rate of skin lesions. Before surgery, each patient received a
local anaesthesia with 0.1% lidocaine in the supine pos-
ition; the skin lesion was excised using a no. 15 blade to
reach the subcutaneous tissues, and the compression
haemostasis was conducted using the wet gauze. In the
treatment group, the HAAM was cut into small pieces
(2 × 2mm) and placed into the bottom and wall of the de-
fects; the wound was then covered with Vaseline gauze
and dressed using the sterile gauze. In the control group,
the wound was directly covered with Vaseline gauze and
dressed using the sterile gauze. The gauze was replaced
the next day postoperatively, and changed every 2 days
until a scab formed. After the scab detached, the patients
returned to the hospital for clinical assessments.
Clinical assessments
During surgery, the haemostasis time and the duration
of operation were recorded. Haemostasis time refers to
the interval from the removal of the lesion to the time
the wound was ready for dressing without bleeding; the
duration of operation refers to the interval from the be-
ginning to the end of the surgery when bandaging was
complete. After surgery, the time to pain disappearance,
scab formation and wound healing, and the wound heal-
ing rate were measured. Time to pain disappearance is
the interval from when the anaesthetic effect ended and
pain was noticeable after surgery to when the pain disap-
peared; time to scab formation is the interval from the
end of surgery to the drying of the wound surface with
the formation of a scab; wound healing time is the inter-
val from the scab formation to when the scab completely
detaches; and the wound healing rate is the difference
between the maximum diameter of the surgical wound
and the maximum diameter of the surgical defect at 15
days after surgery. The diameter of the lesion was classi-
fied as < 5 mm, 5–10 mm and > 10 mm. At 3 months
post operation, the patients were recruited to observe
the wound surface.
Statistical analysis
Statistical analysis was performed using SPSS software
(SPSS 19.0; IBM., Armonk, NY, USA). Student’s t,
chi-square and Fisher’s exact tests were performed to
compare the characteristic data of patients and the data
of clinical assessments between the two groups. Signifi-
cance was accepted when p value < 0.05.
Results
Characteristics of the HAAM
As shown in Fig. 1a, b, c, d, e, the HAAM was a translu-
cent membrane with a thickness of about 10 μm, and no
visible cellular materials were evident; the results of the
SEM scan indicated the presence of the extracellular
matrix components and the collagen scaffold (with the
diameter of 80–100 nm) in the HAAM (Fig. 1f, g).
HAAM implantation enhanced wound healing
In this study, 92 patients (age 32.63 ± 8.64 years) received
HAAM treatment and the other 88 patients (age 30.35 ±
8.33 years) received the conventional treatment (Table 1).
No significant difference was found between these two
groups regarding gender, age and location of skin lesions
(p > 0.05). The HAAM was cut into small pieces and
placed into the bottom and wall of the defects (Fig. 2a, b,
c); so the HAAM treatment took much longer time than
the treatment given to the control group, with mean
values of 22.55 and 20.95min, respectively.
Several enhancements without adverse events or recur-
rences of skin lesions were recorded after the HAAM was
implanted in the defects of 92 patients and control group
(Fig. 2 d, e, f, g, h, i). As shown in Table 2, a significant
reduction in the haemostasis time was seen in the HAAM
treatment group (p < 0.001). Second, the HAAM was
found to accelerate the disappearance of pain after sur-
gery, with a mean value of 6.36 h (p < 0.001). In addition,
when compared with the values of the control group,
HAAM implantation was found to noticeably accelerate
the formation (4.75 days) and detachment (6.70 days) of
scabs postoperatively (p < 0.001). After surgery, when the
diameter of the lesion exceeded 5mm, the HAAM was
found to enhance the wound healing significantly when
compared with the results of the control group (p < 0.05);
nevertheless, this enhancement was not found when the
diameter was less than 5mm. The HAAM notably
reduced the occurrence of bleeding, wound infection and
scar formation after surgery (p < 0.05), and no puckering
or buckling of the healing sites was noted in these patients
after the HAAM treatment (Fig. 3a, b, c, d, e, f, g, h).
Discussion
To our knowledge, this is one of the primary studies to
determine the safety and efficacy of the proof of concept
that HAAM augments the reconstruction of lower third
nasal in humans. The observed advantages of HAAM
implantation include promoting haemostasis, accelerat-
ing the wound healing and pain relief and preventing
bleeding, infection and scar formation; additionally,
HAAM has the benefits of accessibility and ease of use;
this new graft-assisted healing thus possesses significant
potential for extensive clinical application in repairing
skin wounds.
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Before implantation, the HAAM was cut into small
pieces and placed at the bottom and wall of the defect be-
cause large pieces of HAAM could not cover the wound
well. After the small pieces of HAAM were randomly
placed on the moist defect, they were attached firmly to
achieve effective haemostasis and pain relief. After sur-
gery, bleeding induced the formation of a scab, which
likely inhibited the formation of the granulation tissue and
the creep of the epidermis; finally, a pitting scar formed
after the scab detachment [24]. In this study, HAAM
implantation reduced the postoperative bleeding, made
thinner scab and enhanced wound healing with an
improved cosmetic outcome, which may be related to its
function of haemostasis and enhancement of the forma-
tion of granulation tissue within 24 h. However, surgeons
require more surgery time (2–3min) to cut the HAAM
and insert it into the defect piece by piece.
Fresh, cryopreserved or dehydrated AM has been used
successfully for wound healing in experimental models
and patients for several decades, owing to the properties
of reepithelialising, anti-inflammatory and scar preven-
tion without rejection or allergic reaction [7, 25–27]. It
is well known that the cells isolated from the AM release
immunomodulant factors that control the immune re-
sponse and induce a decrease in the inflammatory
response (Th1 and Th17) [28], an increase of regulatory
cells (M2 and Treg) [29], and cytokines, such as basic
fibroblast growth factor, platelet-derived growth factor
and epidermal growth factor, which facilitate the wound
repair and regeneration [30]. Additionally, the dynamic
Table 1 Patients data and duration of operations in HAAM group and control group
Variable HAAM group Control group P value
Gender (F/M) 53/39 57/31 0.32
Age (year, mean ± SD) 32.63 ± 8.64 30.35 ± 8.33 0.09
Location (n)
Ala nasi 59 47
Nasal tip 33 41
Duration of operation (min, mean ± SD) 22.55 ± 3.20 20.95 ± 3.72 < 0.05
HAAM human acellular amniotic membrane, SD standard deviation
Fig. 1 Characteristics of the human acellular amniotic membrane (HAAM). a Gross view of the HAAM before implantation. b, c Images of
hematoxylin and eosin (H&E) staining indicate the resident cells were completely removed after the decellularisation procedures. d, e Cross
-sectional morphology of the HAAM after H&E staining. f, g Scanning electron microscope (SEM) results of the HAAM illustrating the
collagen structure
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interactions between the cytokines and the extracellular
matrix components of AM likely further enhance this
regenerative procedure [31]. At the cellular level, AM
enhanced the proliferation [32] and migration [33] of
keratinocytes through modulating the transforming
growth factor-β pathway, and this cellular response is
essential for wound healing. A similar regenerative
capacity was seen in the decellularised AM as a wound
dressing. Without procuring any cytotoxic effects,
HAAM supported the attachment and proliferation of
dermal fibroblasts, keratinocytes and microvascular
endothelial cells [34], and the delivery of stem cells [35].
Recently, using a rat model, it was indicated that HAAM
was able to promote wound healing and alleviate wound
inflammation and scar formation by enhancing the
secretion of vascular endothelial growth factor and
Table 2 Clinical outcomes and postoperative complications after HAAM implantation surgery
Variable HAAM group Control group P value
Haemostasis time (min, mean ± SD) 3.11 ± 1.14 5.48 ± 1.53 < 0.001
Disappearance time of pain (hour, mean ± SD) 6.36 ± 1.90 11.11 ± 3.55 < 0.001
Time of scab formation (day, mean ± SD) 4.75 ± 1.13 6.84 ± 1.07 < 0.001
Time of scab detachment (day, mean ± SD) 6.70 ± 0.98 8.72 ± 1.99 < 0.001
Healing rate (mm, mean ± SD)
0–5 mm 3.54 ± 0.88 3.29 ± 0.69 0.30
5–10 mm 6.79 ± 1.25 5.26 ± 0.97 < 0.001
> 10 mm 10.27 ± 1.62 8.45 ± 0.93 < 0.05
Bleeding (n) 2 7 < 0.001
Wound infection (n) 4 14 < 0.05
Scar (n) 4 12 < 0.05
HAAM human acellular amniotic membrane, SD standard deviation
Fig. 2 The procedures of human acellular amniotic membrane (HAAM) implantation in the defect of ala nasi and representative cases of the
wound healing at the control and the HAAM implantation groups. a Excision of the lesion. b Cutting the HAAM into small pieces for
implantation. c Pieces of HAAM were placed into the bottom and wall of the defect. d-f Wound healing process of the patient of the control
group. g-i Immediately after excision, 3 days after HAAM implantation and 3 months after HAAM implantation. e More bleeding made thicker
scab in wound in the control group, which would hinder the formation of granulation tissue and the creep of epidermis. h The scab was much
thinner and wetter to form more granulation tissue. f, i After the scab detached from the wound at 3 months postoperatively, the scar after
HAAM treatment was much shallow than that of the control group
Xue et al. Burns & Trauma            (2018) 6:34 Page 5 of 8
alpha-smooth muscle actin [36]. Even though the AM
was solubilised, the acceleration of the wound closure
and prevention of the wound contraction was recorded
in a full-thickness murine wound model [21]. The above
findings in animals suggest encouraging outcomes of
HAAM for the lower third nasal reconstruction in
humans in this study. Although the dehydrated AM has
been reported to treat traumatic wounds to the nasal tip
in one case [16], our study is the first randomised con-
trolled trial to investigate the feasibility of HAAM in the
treatment of circular skin defects for nasal reconstruc-
tion and to demonstrate excellent healing with minimal
aesthetic impact.
Repairing nasal defects, especially the full-thickness
defects, is one of the leading challenges for plastic
surgeons. In traditional closure surgery, some healthy
skin is removed to form an elliptical defection which is
then closed directly; however, this surgery often distorts
the tissue surrounding the defect, causing puckering or
buckling. Graft-assisted healing strategies provide at-
tractive alternative tools for wound closure, especially
the biomaterial-dependent ones [37–40]. While these
biomaterial-based approaches can restore the normal
anatomy, they also limit the loss of the cosmetic unit. In
this study, we pioneered the clinical utilisation of
HAAM for nasal reconstruction, which should add value
for the translation of biomaterial-based therapies.
This preliminary study has several limitations. More
quantitative comparisons of the clinical parameters be-
tween these two groups (such as haemostasis and pain)
Fig. 3 Representative cases of the use of human acellular amniotic membrane (HAAM) for the wound healing at different locations. a, c, e, g
Before HAAM implantation; b, d, f, h 1 month after HAAM treatment
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would perfect the experimental design. It is still
unknown whether the locations of the wound (ala nasi
and nasal tip) affect the healing potential of HAAM.
Histological results were not available after the HAAM
implantation because it is unethical and unacceptable
for the patients to perform a biopsy on healed skin. Add-
itionally, the underlying mechanism of the regenerative
capacity of HAAM remains unclear and needs further
investigation, even though the studies in the field of
fresh or dehydrated AM have provided some clues. It is
still unclear whether this HAAM-based approach is suit-
able for other skin diseases such as burns and diabetic
foot ulcers. A reliable and simple method to standardise
the preparation of HAAM will be largely required to
develop more standardised procedures for its clinical
use. A randomised, multicentre, double-blind and
controlled trial is needed to further test the safety and
efficacy of HAAM implantation.
Conclusion
In this clinical investigation, HAAM implantation was ap-
proved to be feasible and effective for lower third nasal re-
construction. The accelerated wound healing, the reduced
postoperative complications, preservation of the aesthetic
appearance and the ease of use make the HAAM-based
approach a promising procedure for treating skin defects.
This new graft-assisted healing has significant potential
for extensive use in repairing skin wounds.
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